Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1,207 | $803 | $229 | $1 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Cost of Goods Sold | $77 | $15 | $0 | $0 |
| Gross Profit | $1,130 | $788 | $229 | $1 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| R&D Expenses | $500 | $415 | $357 | $241 |
| G&A Expenses | $333 | $259 | $211 | $103 |
| SG&A Expenses | $1,061 | $775 | $390 | $142 |
| Sales & Mktg Exp. | $728 | $515 | $180 | $39 |
| Other Operating Expenses | $0 | $20 | $6 | $0 |
| Operating Expenses | $1,514 | $1,210 | $754 | $383 |
| Operating Income | -$384 | -$422 | -$524 | -$380 |
| % Margin | -31.9% | -52.6% | -228.7% | -43,446.2% |
| Other Income/Exp. Net | -$73 | $5 | $9 | -$54 |
| Pre-Tax Income | -$457 | -$409 | -$513 | -$436 |
| Tax Expense | $9 | $3 | -$4 | $0 |
| Net Income | -$466 | -$412 | -$510 | -$437 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| Weighted Avg Shares Out | 27 | 27 | 25 | 22 |
| Weighted Avg Shares Out Dil | 27 | 27 | 25 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29 | $50 | $0 | $1 |
| Interest Expense | $73 | $13 | $7 | $0 |
| Depreciation & Amortization | $17 | $13 | $34 | $3 |
| EBITDA | -$368 | -$389 | -$472 | -$379 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |